Welcome Guest | Register / Login

Anavex Life Sciences Corp (AVXL) - Financial and Strategic SWOT Analysis Review

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
Anavex Life Sciences Corp - Key Facts
Anavex Life Sciences Corp - Key Employees
Anavex Life Sciences Corp - Key Employee Biographies
Anavex Life Sciences Corp - Major Products and Services
Anavex Life Sciences Corp - History
Anavex Life Sciences Corp - Company Statement
Anavex Life Sciences Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Anavex Life Sciences Corp - Business Description
R&D Overview
Anavex Life Sciences Corp - Corporate Strategy
Anavex Life Sciences Corp - SWOT Analysis
SWOT Analysis - Overview
Anavex Life Sciences Corp - Strengths
Anavex Life Sciences Corp - Weaknesses
Anavex Life Sciences Corp - Opportunities
Anavex Life Sciences Corp - Threats
Anavex Life Sciences Corp - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company's Lifesciences Financial Deals and Alliances
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Anavex Life Sciences Corp, Recent Deals Summary
Section 5 - Company's Recent Developments
Feb 07, 2019: Anavex Life Sciences reports fiscal 2019 first quarter financial results and provides clinical study updates
Jan 02, 2019: Anavex Life Sciences names Walter E Kaufmann, MD as chief medical officer
Dec 12, 2018: Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update
Dec 12, 2018: Anavex Life Sciences reports fiscal year 2018 financial results and provides clinical study update
Oct 30, 2018: First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson's Disease Dementia (PDD)
Oct 26, 2018: Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer's Disease at the 2018 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
Oct 19, 2018: Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Aug 09, 2018: Anavex Life Sciences reports fiscal third quarter 2018 financial results
May 10, 2018: Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results
Mar 05, 2018: Anavex Life Sciences Announces Management Changes
Section 6 - Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Anavex Life Sciences Corp, Key Facts
Anavex Life Sciences Corp, Key Employees
Anavex Life Sciences Corp, Key Employee Biographies
Anavex Life Sciences Corp, Major Products and Services
Anavex Life Sciences Corp, History
Anavex Life Sciences Corp, Subsidiaries
Anavex Life Sciences Corp, Key Competitors
Anavex Life Sciences Corp, Ratios based on current share price
Anavex Life Sciences Corp, Annual Ratios
Anavex Life Sciences Corp, Annual Ratios (Cont...1)
Anavex Life Sciences Corp, Interim Ratios
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Anavex Life Sciences Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Anavex Life Sciences Corp, Performance Chart (2014 - 2018)
Anavex Life Sciences Corp, Ratio Charts
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
Single User License: Report will be emailed in PDF format and can be accessed by a specific user. This License type allows the report to be Printed.
Site License: Report will be emailed in PDF and  allows only employees within the same geographical location within the organization to access it. This License type allows the report to be Printed.
Global Site License: Report will be emailed in PDF format and allows all employees within the organization to access it.  This License type allows the report to be Printed.
Why http://www.marketreportsonline.com/
Published By :GlobalData
Price
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy